Intensity Therapeutics, Inc.

INTS
$3.74 (+ $0.03 + 0.81%)
Last updated: 2026-06-10 21:26 UTC
INTS Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS45828J2024
CUSIP45828J202
Market Price3.74
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.55
Market Cap$24.4M
Book Value0.15
Price to Book2.766
Beta4.24
52w High3.17
52w Low0.18
Next Earnings DateN/A

Intensity Therapeutics, Inc. trades under ticker INTS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US45828J2024, CUSIP 45828J202.

About the Company
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Price History